Company Overview of Celgene Srl
Celgene Srl discovers, develops, and commercializes drugs and therapies to treat cancer and inflammatory diseases in Italy. It markets and sells REVLIMID, an oral immunomodulatory drug for multiple myeloma, myelodysplastic syndromes (MDS), and mantle cell lymphoma; ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers; POMALYST/IMNOVID for the treatment of multiple myeloma; and VIDAZA, a pyrimidine nucleoside analog to treat intermediate-2 and high-risk MDS, chronic myelomonocytic leukemia, and acute myeloid leukemia (AML). The company is based in Milan, Italy. Celgene Srl operates as a subsidiary of Celgene Corporation.
Viale Della Liberazione 13
Milan, MI 20124
39 02 636901
Key Executives for Celgene Srl
Celgene Srl does not have any Key Executives recorded.
Similar Private Companies By Industry
|Arterra Bioscience s.r.l.||Europe|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|NYC2012, Inc.||United States|
|The Advertising Council, Inc.||United States|
|Rush University||United States|
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.
To contact Celgene Srl, please visit --. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.